Literature DB >> 15242486

Non-alcoholic steatohepatitis in type 2 diabetes mellitus.

Parijat Gupte1, Deepak Amarapurkar, Subhash Agal, Rajiv Baijal, Pramod Kulshrestha, Snehansu Pramanik, Nikhil Patel, Aruna Madan, Anjali Amarapurkar.   

Abstract

BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH) is commonly associated with type 2 diabetes mellitus (DM). Prevalence of NASH in type 2 DM has not been well studied and there is an epidemic rise in type 2 DM in Asian and Western populations. Its association with chronic liver disease in the form of NASH makes it an important health problem. Hence we have studied its prevalence and correlation of biochemical parameters with histological grades of non-alcoholic fatty liver disease (NAFLD) in otherwise asymptomatic type 2 DM patients.
METHODS: One hundred and forty-eight individuals were screened. Forty-eight individuals were excluded due to history of alcohol intake or liver disease as a result of other causes. One hundred non-alcoholic individuals with type 2 DM underwent abdominal ultrasonography (US abdomen). Forty-nine patients had evidence of fatty liver on US abdomen, and 32 of these 49 patients underwent liver biopsy.
RESULTS: Four of 32 (12.5%) individuals had steatosis alone. Mild, moderate and severe NASH was present in 21/32 (65.5%), 4/32 (12.5%) and 3/32 (9.35%), respectively. Fibrosis was present in 7/32 (21.8%) patients (four grade 1 and three grade 3). There was no significant difference in body mass index (BMI), transaminase levels, serum cholesterol and triglyceride levels among patients with non-alcoholic fatty liver disease.
CONCLUSION: We conclude that the prevalence of NASH is high in type 2 DM patients and liver biopsy is the only investigation to differentiate between non-alcoholic fatty liver and steatohepatitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242486     DOI: 10.1111/j.1440-1746.2004.03312.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  87 in total

1.  Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects.

Authors:  H B Holt; S H Wild; P J Wood; J Zhang; A A Darekar; K Dewbury; R B Poole; R I G Holt; D I Phillips; C D Byrne
Journal:  Diabetologia       Date:  2005-12-02       Impact factor: 10.122

Review 2.  NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes.

Authors:  Elisabetta Bugianesi; Ester Vanni; Giulio Marchesini
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

Review 3.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

Review 4.  Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment.

Authors:  Steven D Lidofsky
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

5.  Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma.

Authors:  Ankita Makol; Shruthi Kanthaje; Radha K Dhiman; Naveen Kalra; Yogesh K Chawla; Anuradha Chakraborti
Journal:  Exp Biol Med (Maywood)       Date:  2017-11-29

Review 6.  Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Claudia R L Cardoso; Gil F Salles
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 7.  Stable isotope-based flux studies in nonalcoholic fatty liver disease.

Authors:  Arthur McCullough; Stephen Previs; Takhar Kasumov
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 8.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004.

Authors:  Yvonne N Flores; Hal F Yee; Mei Leng; José J Escarce; Roshan Bastani; Jorge Salmerón; Leo S Morales
Journal:  Am J Gastroenterol       Date:  2008-07-30       Impact factor: 10.864

10.  Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients.

Authors:  Jang Hyun Koh; Young Goo Shin; Soo Min Nam; Mi Young Lee; Choon Hee Chung; Jang Yel Shin
Journal:  Diabetes Care       Date:  2008-10-03       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.